Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003635 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003635: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00003635 is a Phase 2 study that has completed, run by GlaxoSmithKline. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003635, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
Interventions
- DRUG nelarabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00003635 record still lists
NCT00003635 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which nelarabine is the first listed.
NCT00003635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003635 about?
NCT00003635 is a clinical study titled "506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
What is the current status of trial NCT00003635?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-01. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00003635?
The interventions under investigation include: nelarabine (DRUG).
Who is sponsoring clinical trial NCT00003635?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia